Bristol-Myers Squibb (NYSE:BMY) Cut to “Buy” at Wall Street Zen
Wall Street Zen lowered shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) from a strong-buy rating to a buy rating in a research report report published on Friday. A number of other research analysts have also recently commented on the stock. The Goldman Sachs Group restated a “neutral” rating and set a $55.00 price target […]
Wall Street Zen lowered shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) from a strong-buy rating to a buy rating in a research report report published on Friday. A number of other research analysts have also recently commented on the stock. The Goldman Sachs Group restated a “neutral” rating and set a $55.00 price target […]
